Pd41-11 Longitudinal Follow Up of Multicenter Study of Ugn-101 for Upper Tract Urothelial Cancer

You have accessJournal of UrologyBladder Cancer: Upper Tract Transitional Cell Carcinoma III (PD41)1 May 2024PD41-11 LONGITUDINAL FOLLOW UP OF MULTICENTER STUDY OF UGN-101 FOR UPPER TRACT UROTHELIAL CANCER Solomon L. Woldu, Brett Johnson, Katie S. Murray, Hiroko Miyagi, Wade Sexton, Isamu Tachibana, Hristos Kaimakliotis, Joseph Jacob, Rian Dickstein, Jennifer Linehan, Alan Nieder, Marc Bjurlin, Daniel Heidenberg, Mitchell Humphreys, Saum Ghodoussipour, Marcus L. Quek, Michael O'Donnell, Brian Eisner, Surena Matin, Adam S. Feldman, and Yair Lotan Solomon L. WolduSolomon L. Woldu , Brett JohnsonBrett Johnson , Katie S. MurrayKatie S. Murray , Hiroko MiyagiHiroko Miyagi , Wade SextonWade Sexton , Isamu TachibanaIsamu Tachibana , Hristos KaimakliotisHristos Kaimakliotis , Joseph JacobJoseph Jacob , Rian DicksteinRian Dickstein , Jennifer LinehanJennifer Linehan , Alan NiederAlan Nieder , Marc BjurlinMarc Bjurlin , Daniel HeidenbergDaniel Heidenberg , Mitchell HumphreysMitchell Humphreys , Saum GhodoussipourSaum Ghodoussipour , Marcus L. QuekMarcus L. Quek , Michael O'DonnellMichael O'Donnell , Brian EisnerBrian Eisner , Surena MatinSurena Matin , Adam S. FeldmanAdam S. Feldman , and Yair LotanYair Lotan View All Author Informationhttps://doi.org/10.1097/01.JU.0001008568.76803.f1.11AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract INTRODUCTION AND OBJECTIVE: UGN-101 is a novel therapeutic for the treatment of upper tract urothelial cancer (UTUC) but there is a lack of longitudinal data on efficacy. This study evaluated a large multicenter cohort of patients treated with UGN-101, with longest follow up available in the literature. METHODS: Data was collected from 15 centers on patients treated with UGN-101 for UTUC. Recurrence free survival (RFS) was calculated only for patients who had no evidence of disease following UGN-101 induction. Progression free survival (PFS) was calculated for all patients treated with UGN-101. Disease progression was defined as: i) grade progression from low-grade to high-grade disease, ii) stage progression, or iii) development of metastatic disease. Receipt of maintenance was defined as dichotomously, although practice patterns varied. RESULTS: There were 136 cases of UTUC treated with UGN-101 with a cumulative median (IQR) follow up of 22 (12-27) months including 107 cases of LGTa UTUC. PFS was 87% at 24 months. Within the subset of 53 cases with LGTa UTUC without evidence of disease following UGN-101 induction – the median time to recurrence was not reached. RFS at 24-months was 86%. Among initial responders, 30% received maintenance therapy. RFS at 24 months was 100% and 61% for patients who received maintenance versus no maintenance, respectively (log rank 0.014). There were 9 cases of high-grade and presumed non-invasive disease treated with UGN-101 who had follow-up available. The median risk of progression was 50% at 12 months. In the subset of 4 cases with HGTa disease who had a negative initial endoscopic evaluation – half had recurred by 10 months. CONCLUSIONS: UGN-101 treatment appears to demonstrate favorable recurrence free survival rates in patients with LGTa UTUC. Administration of maintenance appears to be associated with significantly better RFS. Due to small numbers of patients with high-grade disease, our analysis is limited however there is significant concern for high risk of recurrence and progression in this cohort. Download PPTDownload PPT Source of Funding: None © 2024 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 211Issue 5SMay 2024Page: e890 Advertisement Copyright & Permissions© 2024 by American Urological Association Education and Research, Inc.Metrics Author Information Solomon L. Woldu More articles by this author Brett Johnson More articles by this author Katie S. Murray More articles by this author Hiroko Miyagi More articles by this author Wade Sexton More articles by this author Isamu Tachibana More articles by this author Hristos Kaimakliotis More articles by this author Joseph Jacob More articles by this author Rian Dickstein More articles by this author Jennifer Linehan More articles by this author Alan Nieder More articles by this author Marc Bjurlin More articles by this author Daniel Heidenberg More articles by this author Mitchell Humphreys More articles by this author Saum Ghodoussipour More articles by this author Marcus L. Quek More articles by this author Michael O'Donnell More articles by this author Brian Eisner More articles by this author Surena Matin More articles by this author Adam S. Feldman More articles by this author Yair Lotan More articles by this author Expand All Advertisement PDF downloadLoading ...